Cargando…

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction

Objective: To explore the treatment effect of statins used together with clopidogrel on cerebral infarction (CI). Methods: One hundred and thirty non-clopidogrel resistant patients were divided into a dynamic clopidogrel resistant (DCR) group and a continuous Non clopidogrel resistance (NCR) group....

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Hong Ting, Chen, Yong Yuan, Li, Xiao Ying, Luo, Jian Hua, Zhong, Guang Hong, Hu, Jia Jia, Zhang, Min, Zhou, Bo Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526974/ https://www.ncbi.nlm.nih.gov/pubmed/34690774 http://dx.doi.org/10.3389/fphar.2021.738562

Ejemplares similares

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism
por: Gao, Nanyong, et al.
Publicado: (2022)

Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions
por: Kong, Qihui, et al.
Publicado: (2023)

Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
por: Liu, Xiao-yun, et al.
Publicado: (2020)

Exploring the Role of CYP3A4 Mediated Drug Metabolism in the Pharmacological Modulation of Nitric Oxide Production
por: Pérez-del Palacio, José, et al.
Publicado: (2017)

Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study
por: Azzahhafi, Jaouad, et al.
Publicado: (2022)

Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
por: Liu, Shuaibing, et al.
Publicado: (2017)

Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform
por: Kabir, Md, et al.
Publicado: (2022)

Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response
por: Zhang, J. E., et al.
Publicado: (2017)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam
por: Fashe, Muluneh M., et al.
Publicado: (2023)

The Modulatory Role of CYP3A4 in Dictamnine-Induced Hepatotoxicity
por: Li, Zhuo-Qing, et al.
Publicado: (2018)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
por: Contreras-Castillo, Stephania, et al.
Publicado: (2021)

In Vitro Assessment of the Interaction Potential of Ocimum basilicum (L.) Extracts on CYP2B6, 3A4, and Rifampicin Metabolism
por: Kumar, Saneesh, et al.
Publicado: (2020)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
por: Damoiseaux, David, et al.
Publicado: (2022)

Genetic variation in the 3′-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance
por: Swart, Marelize, et al.
Publicado: (2014)

Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro
por: Zhou, Xiao-Yang, et al.
Publicado: (2019)

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
por: Danielak, Dorota, et al.
Publicado: (2016)

Metabolomics-based discovery of XHP as a CYP3A4 inhibitor against pancreatic cancer
por: Yang, Yuting, et al.
Publicado: (2023)

Time-dependent inhibition of CYP3A4-mediated midazolam metabolism by macrolide antibiotics in CYP3A4 genetic variants: Comparison with testosterone metabolism
por: Akiyoshi, Takeshi, et al.
Publicado: (2021)

Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C9*72-*75 in the Chinese Han population
por: Zhao, Fang-Ling, et al.
Publicado: (2022)

Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resin
por: Al-Jenoobi, Fahad I., et al.
Publicado: (2014)

Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism
por: Tang, Peng-fei, et al.
Publicado: (2020)

Characterization of the genetic variation present in CYP3A4 in three South African populations
por: Drögemöller, Britt, et al.
Publicado: (2013)

Identification and Analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in Cynomolgus Macaques
por: UNO, Yasuhiro, et al.
Publicado: (2014)

Reductive metabolism of oxymatrine is catalyzed by microsomal CYP3A4
por: Liu, Wenqin, et al.
Publicado: (2015)

Monoester-Diterpene Aconitum Alkaloid Metabolism in Human Liver Microsomes: Predominant Role of CYP3A4 and CYP3A5
por: Ye, Ling, et al.
Publicado: (2013)

Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro
por: Lin, Qian-Meng, et al.
Publicado: (2019)

Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities
por: Hurkmans, Evelien G. E., et al.
Publicado: (2020)

CYP3A4 and CYP3A5 genotyping by Pyrosequencing
por: Garsa, Adam A, et al.
Publicado: (2005)

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites
por: F. Martins, Margarida L., et al.
Publicado: (2022)

Potential Metabolic Drug–Drug Interaction of Citrus aurantium L. (Rutaceae) Evaluating by Its Effect on 3 CYP450
por: Zhou, Lu, et al.
Publicado: (2018)

Ontogeny of CYP3A and UGT activity in preterm piglets: a translational model for drug metabolism in preterm newborns
por: Buyssens, Laura, et al.
Publicado: (2023)

Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention
por: Sun, Hong, et al.
Publicado: (2016)

Frog intestinal perfusion to evaluate drug permeability: application to p-gp and cyp3a4 substrates
por: Yerasi, Neelima, et al.
Publicado: (2015)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine
por: Ye, Zhize, et al.
Publicado: (2022)

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017)

CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry
por: Molden, Espen, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4m1s0fm466ooapjisnm3nqkkds